Sort by

Send to

Choose Destination

Links from PubMed

Items: 6


Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082.


Biomarker assessment and molecular testing for prognostication in breast cancer.

Kos Z, Dabbs DJ.

Histopathology. 2016 Jan;68(1):70-85. doi: 10.1111/his.12795. Review. Erratum in: Histopathology. 2016 May;68(6):946.


Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.

Kanaya N, Somlo G, Wu J, Frankel P, Kai M, Liu X, Wu SV, Nguyen D, Chan N, Hsieh MY, Kirschenbaum M, Kruper L, Vito C, Badie B, Yim JH, Yuan Y, Hurria A, Peiguo C, Mortimer J, Chen S.

J Steroid Biochem Mol Biol. 2016 May 3. pii: S0960-0760(16)30131-5. doi: 10.1016/j.jsbmb.2016.05.001. [Epub ahead of print] Review.


Current molecular diagnostics of breast cancer and the potential incorporation of microRNA.

Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA.

Expert Rev Mol Diagn. 2009 Jul;9(5):455-67. doi: 10.1586/erm.09.25. Review.


Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation.

Farabaugh SM, Boone DN, Lee AV.

Front Endocrinol (Lausanne). 2015 Apr 24;6:59. doi: 10.3389/fendo.2015.00059. Review.


Novel Molecular Markers for Breast Cancer.

Inoue K, Fry EA.

Biomark Cancer. 2016 Mar 13;8:25-42. doi: 10.4137/BIC.S38394. Review.

Items per page

Supplemental Content

Support Center